Sleep Disorder
Sleep disorders (SDs), including insomnia, hypersomnia, and delayed sleep phase, are common symptoms in patients with various disorders and the general population. Epidemiological data indicate that the prevalence of various SDs in the general population ranges from 0.047 to 50.5%. The most common SD is insomnia followed by sleep apnoea, restlessness syndrome, nightmares, sleep talking, sleepwalking and narcolepsy.
Causes of Psychotic Disorder
Sleep is divided into two periods according to changes in eye movement: non-rapid eye movement (NREM) and rapid eye movement (REM). Persons with SD normally have sleep-wake complaints of dissatisfaction in the quality, timing, and amount of sleep. The consequences of sleep-wake disorders are daytime distress and impairment of sleep. Persistent sleep disturbances including insomnia and excessive sleepiness are confirmed as risk factors for later development of mental illness and substance abuse disorders. Long-term SDs cause anxiety, depression and/or fear and can lead to decreased mental activity and increased risks of cardiovascular disease, dementia, mental illness, and hypogonadism.
Dopamine (DA) and Glutamate in Psychotic Disorder
GABA, melatonin, and orexin receptors are known as pharmacodynamic targets for behavioral therapies that combat insomnia. The GABA receptor is a gated chloride channel receptor, which can induce rapid inhibitory post synaptic potential (IPSP). Most of the target sites of sleeping tablets are benzodiazepine binding sites on the GABA receptor. When the signaling of the GABA receptor is weakened, sleep maintenance will also be shortened. In addition, 5-HT is a neurotransmitter widely distributed in the central nervous system of mammals and is involved in sleep-wake cycle regulation. Injecting 5-HTP or 5-HT1A receptor agonists increases slow-wave sleep (SWS) and reduces sleep latency in mammals. By targeting the receptor, it also has a variety of biological activities such as anti-oxidation, cell protection, anti-proliferation, anti-inflammatory, sedative, and hypnotic, and reduces the complications of sleep disorders.
Fig.1 Illustration of the mechanisms in sleep disorder. (Guo, 2020)
Treatment Methods of Psychotic Disorder
Sedative-hypnotic drugs, including benzodiazepines and non-benzodiazepines, are commonly used to treat SD but are not suitable for prolonged use. In fact, patients may not be able to tolerate the various side effects of these drugs, which include rebound withdrawal effects, disturbed sleep structure, drowsiness, memory disorders and bad behaviors during sleep. In addition to the abovementioned drugs, antidepressants, antipsychotics, and antihistamines can also be used to treat SD due to their sedative-hypnotic effects.
Creative Biolabs can provide antibodies, activators, antagonists, and detection kits for neurological disease research. Our goal is to provide customers with professional and efficient help and jointly promote new discoveries in neuroscience. Please feel free to contact us if you have any questions.
Products Name | Target | Cat.No. |
Mouse Anti-GABA Monoclonal Antibody (5A9) | GABA | NAB-0720-Z2121 |
GABA [GABA Inhibitor] | GABA | MOD2005ZP92 |
(R)-Baclofen [GABAB Receptor Agonist] | GABAB Receptor | MOD2005ZP243 |
Melatonin [Endogenous hormone Agonist at MT1 and MT2 receptors] | MT1, MT2 | MOD2005ZP968 |
Melatonin ELISA Kit [Colorimetric] | Melatonin | NPP2011ZP376 |
Buspirone hydrochloride [5-HT1A Agonist] | 5-HT1A Receptor | MOD2005ZP306 |
Reference
- Guo, J.; et al. Uncovering the pharmacological mechanism of the effects of the Banxia-Xiakucao Chinese Herb Pair on sleep disorder by a systems pharmacology approach. Scientific reports. 2020, 10(1): 1-12.
- NeuroMab™ Anti-CD32b Antibody(NRP-0422-P1803) (Cat#: NRP-0422-P1803)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P1684) (Cat#: NRP-0422-P1684)
- NeuroMab™ Mouse Anti-EFNB2 Monoclonal Antibody (CBP1159) (Cat#: NAB-0720-Z4396)
- NeuroMab™ Anti-GD2 Antibody(NRZP-1222-ZP767) (Cat#: NRZP-1222-ZP767)
- NeuroMab™ Anti-pTau Antibody(NRP-0422-P1719) (Cat#: NRP-0422-P1719)
- NeuroMab™ Anti-SEZ6 Antibody(NRP-0422-P515) (Cat#: NRP-0422-P515)
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P2275) (Cat#: NRP-0422-P2275)
- NeuroMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- NeuroMab™ Anti-Amyloid Beta 1-15 Antibody(NRP-0422-P867) (Cat#: NRP-0422-P867)
- Human Microglia Cell Line HMC3, Immortalized (Cat#: NCL-2108P38)
- Human Brain Microvascular Endothelial Cells (Cat#: NCL-2103-P133)
- Human Glioblastoma Cell Line SF126 (Cat#: NCL-2108P35)
- Mouse Retinal Ganglion Cell Line RGC-5 (Cat#: NCL2110P154)
- iNeu™ Microglia (Cat#: NCL-7P018)
- Immortalized Human Cerebral Microvascular Endothelial Cells (Cat#: NCL-2108-P020)
- Human Astrocytes (Cat#: NCC20-9PZ01)
- Human Neurons Isolated from Cortex (Cat#: NCL-21P6-023)
- Rat Muller Cell (Cat#: NCL2110P040)
- Human Brain Astroblastoma U-87 MG (Cat#: NCL2110P117)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- AAV2/9-hEF1a-DIO-mCherry-P2A-TetTox-WPRE-pA (Cat#: NTA-2012-ZP268)
- pAAV-EF1a-DIO-EGFP-WPRE (Cat#: NTA-2012AD-P285)
- AAV2/9-hSyn-Flpo-EGFP-WPRE-pA (Cat#: NTA-2012-ZP149)
- pAAV-syn-jGCaMP8f-WPRE (Cat#: NTA-2106-P061)
- rAAV-CAG-DIO-G-Flamp1 (Cat#: NRZP-0722-ZP719)
- pAAV-hSyn-DIO-XCaMP-R-WPRE (Cat#: NTA-2012AD-P508)
- PRV-CAG-EGFP (Cat#: NTA-2011-ZP14)
- Dextran, Cy5 Labeled, 2000 kDa (Cat#: NRZP-0722-ZP22)
- Dextran-FITC (Cat#: NTA-2011-ZP110)
- pAAV-syn-jGCaMP8m-WPRE (Cat#: NTA-2106-P062)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)